Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. “We had little access to information. He pays special attention to the field of translational oncology of large-cell lung cancer. His curiosity and an “enthusiasm for medicine” took him to medical school, and he trained in internal medicine under the tutelage of Ciril Rozman at the Hospital Clínico de Barcelona in the early 1970s. He has participated in respiratory disease clinical trials, publications in prestigious biomedical journals, and at scientific congresses. In contrast with non–small cell lung cancer (NSCLC), it is not associated with specific somatic mutations ().The prognosis for patients with SCLC has not improved and treatment has remained substantially the same for the last 25 years. But there are signs that we could finally be approaching a turning point, and Rafael Rosell is one of the leading lights taking us there. MLA Citation Felip E, Rosell R. Felip E, & Rosell R Felip, Enriqueta, and Rafael Rosell. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) Rosario Garcia-Campelo, Oscar Arrieta, Bartomeu Massuti,... Miguel Angel Molina-Vila, Rafael Rosell; On behalf of The Spanish Lung Cancer Group (SLCG) Dr. Romero holds a degree in Medicine and a PhD from the Autonomous University of Barcelona, and trained as a Thoracic Surgeon at Vall d'Hebron University Hospital, Barcelona where she remains to this day and also serves as Associate Professor of Medicine. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Rosell, Rafael a; Karachaliou, Niki b; Arrieta, Oscar c. Current Opinion in Oncology: January 2020 - Volume 32 - Issue 1 - p 37–43. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. He first became involved in lung cancer research in the early 1980s, and witnessed first-hand the revolution brought about by the PCR technique in 1985. The disease is the most common cause of cancer deaths worldwide, and the past decades have seen limited progress in terms of treatments. Rafael Rosell, MD | Authors. “His creativity and insane drive have enabled him to accomplish more than anyone else in the field”, says David Jablons, Chief of Thoracic Surgery at the University of California, San Francisco and leader of a translational laboratory. And then, in 2004, came “the most important discovery in the field of lung cancer”, says Rosell: the discovery that mutations in the epidermal growth factor receptor were the primary drivers of a subset of lung cancers. Adjuvant cisplatin-based chemotherapy is standard use in adenocarcinomas and squamous cell lung cancer patients with stage IIA, IIB or IIIA disease who have undergone complete surgical resection . In this issue of, Softly spoken and thoughtful in conversation, Rosell is too modest to stake a claim to any position of pre-eminence, but speaks with the assurance of someone at the top of his game. Dr Viteri graduated in Medicine from the Universidad de Navarra in 2002 and was board certified in Medical Oncology. NSCLC is the most common type of lung cancer, accounting for ~80–85% of all lung cancer cases . Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients Transl Lung Cancer Res. “There's no one that I can think of who has crossed so many borders, intellectually, culturally, translationally, educationally, than Rafael.”, Not everyone, though, shares in the mood of optimism. The turn of the century brought quantitative PCR and the ability to quantify the expression of genes, opening up the possibility of customising chemotherapy on the basis of the expression of key genes, and of developing biomarkers to predict which patients would best benefit from different treatments. Buy. Novel molecular targets for the treatment of lung cancer. Between 2008-2009 he practiced in the Medical Oncology Department, Breast Cancer Unit, Hospital Sant Joan de Reus. Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer (Lu, Y., et al Nature Medicine, 2020) Rafael Rosell Martyna Filipska Dr. Moya holds a degree in Medicine from the Autonomous University of Barcelona and specialized in Medical Oncology at the Parc Taulí University Hospital. He was staff member at Medical Oncology Department of the Hospital Mutua Terrassa, Terrassa in 2016, Hospital Sant Joan de Déu at Martorell and Clínica Rotger (Quirónsalud Group) at Mallorca, before joining the IOR team. We hypothesized that progression-free survival could be influenced both … Sign up for regular alerts to keep abreast of the latest news about treatments, research and advances in the fight against cancer, as well as the activities of the Dr. Rosell Oncology Institute. In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. Filipino star Rafael Rosell talks ‘OFW The Movie’ The actor is in Dubai to attend a special screening of the film on October 11 Published: October 10, 2019 13:11 Irish Eden Belleza, Videographer Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. Now the Head of the Medical Oncology Service and Scientific Director for Oncology for the Catalan Institute of Oncology, at the Germans Trias i Pujol University Hospital in Badalona, Barcelona, he grew up near Montserrat National Park, in the mountains north of the city. Back; The Lancet; The Lancet Child & Adolescent Health The Lung Cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning issues. LUNG AND MEDIASTINUM: Edited by Robert Pirker. From Japan and Korea through Europe and the USA, Rosell has brought together colleagues from across the globe to bring the latest basic science to bear on patients, inspired by his passion and knowledge. Commentary: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer (Lu, Y., et al Nature Medicine, 2020) Rafael Rosell Martyna Filipska Oncogene 1993 ;8: 2407 - 2412 Web of Science In contrast with non–small cell lung cancer (NSCLC), it is not associated with specific somatic mutations ().The prognosis for patients with SCLC has not improved and treatment has remained substantially the same for the last 25 years. Readers will find searched for answers in multiple facets of lung cancer. He was the first to demonstrate a benefit in terms of progression-free survival in non-small-cell lung cancer patients with EGFR mutations treated with Tarceva® in the EURTAC trial. Lung Cancer “At that time we were still at the beginning of what became known as modern medicine”, he recalls. Between 2010 and 2014, he worked as attending physician and clinical researcher in the Medical Oncology Department, Digestive and Genitourinary Tumor Section, at the Hospital del Mar, Barcelona. “It was a difficult time in my youth”, he recalls. He is Founder and President of the Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP). “Many colleagues from time to time will say that cancer is impossible to treat, or that cancer is impossible to understand. Also Dr García has participated as investigator in clinical trials, he has participated at national and international congresses and is also co-author of several articles published in biomedical journals. Sometimes there's a little frustration or nihilism”, says Rosell. 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. Clin Cancer Res5:1849-1854, 1999. Rafael Rosell, MD. Dr. Rubinstein holds a degree in Medicine from Universidad de la República, Uruguay (UDELAR), specialism in Internal Medicine, a PhD in Health Sciences, International University of Catalonia and a Master’s in Healthcare Management, University of Murcia. "Lung cancer is the most frequent and lethal tumor in which preventative screening has not yet had a major impact on early diagnosis." We did a systematic search of PubMed using the search terms “lung cancer,” and “ILK” in one search, and “lung cancer,” and “SHP2” in another search, each for articles published between Jan 1, 2010, and Oct 31, 2018. Rafael Rosell's 881 research works with 37,763 citations and 4,258 reads, including: Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. The once dilapidated port is now one of the world's biggest tourist magnets, “overwhelmed by visitors” says Rosell, and almost unrecognisable from the place he grew up in during the 1950s. Lung Cancer. Niki Karachaliou, Rafael Rosell, Santiago Viteri • Inhibition of insulin-like growth factor receptor: end of a targeted therapy? 2 … Medicine. Dr. Romero has coathored numerous publications in prestigious biomedical journals and is an active member of the SLCG (Spanish Lung Cancer Group), SECT (Spanish Society of Thoracic Surgery), SEPAR (Spanish Society for Respiratory Pathology) and IASLC (International Association for the Study of Lung Cancer). We were among the first to perform a large scale screening for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma patients, at the time that experts in the field were denying the relevance of this genetic alteration. Rafael Rosell. This Journal. Rosell's group sits at the centre of a collaborative empire on which the sun never sets. He worked as a physician in the Oncology Department of the Hospital General Mateu Orfila in Menorca in 2007 before joining the IOR team. Image, Download Hi-res People of my generation were the same in many cases, raising ourselves a little on our own and seeking knowledge for the sake of our own curiosity.”. Some content has been sourced from the NCI. Lung cancer is the most frequent cancer worldwide. Rafael Rosell, MD. The Lung Cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning issues. DOI: https://doi.org/10.1016/S0140-6736(13)61763-8, We use cookies to help provide and enhance our service and tailor content and ads. Dr. Maestre graduated in Medicine and Surgery from the Universidad de Zaragoza in 1968; he was board certified in Thoracic Surgery by the Hospital Universitario Vall d’ Hebron, Barcelona. • The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. He has served on the Scientific Program Sub-Committee (non-small-cell lung cancer, metastatic) for the annual congress of the European Medical Oncology Society (ESMO). 2016 Oct;5 ... Santiago Viteri 3 , Daniela Morales-Espinosa 3 , Rafael Rosell 4 Affiliations 1 Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain. He is currently Head of Pneumology at the HU General de Catalunya. We can explain to them that it's not all black or white, and we are now trying to select treatments based on biomarkers. Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. Dr. Rosell is a member of the International Association for the Study of Lung Cancer (IASLC) and was Scientific Chair of their 2005 World Conference on Lung Cancer. Affiliations. Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition. On the 1 st Chinese Lung Cancer Precision Medicine Forum & 4 th National Cancer Institute Annual Symposium held in Beijing China in May 2016, Professor Rafael Rosell was invited to present his speech on the topic “A limited number of signaling pathways are used reiteratively in resistance to targeted therapy in lung cancer and other solid tumors” (Figure 1). Dr. Aguilar graduated in Medicine and Surgery from the University of Havana, Cuba in 2005 and was board certified in Medical Oncology at the Hospital Universitari Mutua Terrassa, University of Barcelona. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. Furthermore, 610,000 out of 2.8 million cancer-related deaths are caused by lung cancer, making it a “deadly cancer.” Lung cancer is histologically divided into two main types: small cell lung cancer and non-small cell lung cancer (NSCLC). Dr González graduated in Medicine from the University of Lleida in 2003 and specialized in Medical Oncology at the Hospital de la Santa Creu i Sant Pau in 2008. Rafael Rosell and Niki Karachaliou served as the unpaid Guest Editors for the focused issue. Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of cancer worldwide, or more than 180,000 cases per year. Transl Lung Cancer Res. However, the presence of EGFR mutations can only imperfectly predict outcome. He gained his PhD from the Universidad Autónoma de Barcelona in 1992 and was Head of Service at the Hospital Germans Trias i Pujol, Badalona, until 1995, and at the Hospital Universitario Vall d'Hebron until 2009 where he directed the surgical lung transplant program for 15 years, which was successful in reaching the figure of 500 transplants. She also worked as a physician in the Medical Oncology Department of the Hospital Santa María Nai de Ourense in 2006 and 2007. It has beenevaluated in non–small-cell lung cancer (NSCLC) as front-line chemotherapyin a comprehensive phase II evaluation. “But there is accumulated knowledge, and we are beginning to see how this real knowledge can be almost immediately applied when we are treating patients. Previous experience at Hospital de Puigcerdà, Vallés Cancer Institute, ALTHAIA Foundation, Manresa University Healthcare Network, Sant Bernabé de Berga Hospital Foundation and the Baselga Oncology Institute (IOB), Barcelona. Dr Rosell talks to ecancertv at the Future Horizons In Lung Cancer conference about understanding the mechanisms of immunotherapy and how it has changed the process of treatment. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. You agree to the processing of your health data for the purposes described in the, C/ Pedro i Pons 1, Sant Cugat del Vallés 08028, Tel. ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free survival with dacomitinib.The mature overall survival (OS) analysis for the intention-to-treat population is presented here. Immunotherapy can be of substantial benefit to the patient, due to it's ability to shrink lung cancer … Since 2014, he has worked as attending physician at the General Hospital of Catalonia, and as part of the Dr. Rosell Oncology Institute team in that same hospital. Please enter a term before submitting your search. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Dr García Mosquera holds a degree in Medicine from the Universidad Tecnológica Equinoccial (Ecuador), he was board certified in Medical Oncology by the Catalan Institute of Oncology (ICO) at the Hospital Universitari Germans Trias i Pujol from Badalona. doi: 10.1097/CCO.0000000000000590. Rosell R, Calvo R, Sánchez JJ, et al: Geneticsusceptibility associated with rare HRAS1 variable number of tandem repeatsalleles in Spanish non-small-cell lung cancer patients. Cancer Biology and Precision Medicine Rafael Rosell. He is a member of SEPAR (Spanish Society for Pneumology and Thoracic Surgery), ALAT (Latin American Thorax Association), ERS (European Respiratory Society), SMU (Uruguayan Medical Syndicate), SOCAP (Catalan Society for Pneumology) and SCATT (Catalan Society for Prevention & Control of Smoking). “There are others who have accomplished a lot, but no one has done more to shake it up especially in a translational capacity and put the ‘rubber to the road’ than Rafael”, he says. "Lung Cancer." Rafael Rosell's 898 research works with 38,890 citations and 4,209 reads, including: RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Even among the ranks of cancers, lung cancer is particularly vicious. Dr. Pons graduated in Medicine from the University of Barcelona in 2005, and was board certified in Medical Oncology in 2010 by the Catalan Institute of Oncology (ICO), University Hospital of Bellvitge. patients with health insurance: 902 39 29 19, Copyright © 2015 Instituto Oncológico Dr. Rosell. Cancer Biology and Precision Medicine Rafael Rosell. In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. However, 30% to 70% of patients undergoing resection develop recurrence and die of their disease. Copyright © 2021 Elsevier Inc. except certain content provided by third parties. Dr. Martínez Bueno holds a degree in Medicine and Surgery from the University of Cantabria and trained in Medical Oncology at the Hospital Donostia, Gipuzkoa. Although lung cancer is not the most common cancer, it is still the leading cause of cancer death in men throughout the world, accounting for 29% of all cancer deaths in men in the European Community countries. Rosell sounds a cautious note of optimism that it could be personalised therapy that, at last, delivers the solution to a problem that has until now proven beyond the reach of medical science. We were among the first to perform a large scale screening for epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma patients, at the time that experts in the field were denying the relevance of this genetic alteration. Dr. Rafael Rosell to lead the lung cancer unit at Hospital Quirón Teknon. He pays special attention to the field of translational oncology of large-cell lung cancer. Prof Rafael Rosell, MD . Transl Lung Cancer Res. Rafael Rosell: leading the long march against lung cancer. Privacy Policy   Terms and Conditions. Rosell R, Li S, Skacel Z, et al. In this study, we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients. Even among the ranks of cancers, lung cancer is particularly vicious. November 02, 2004. By continuing you agree to the use of cookies. Pemetrexed in Front-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Gene fusions represent novel predictive biomarkers for advanced non-small cell lung cancer (NSCLC). Experience in Medical Oncology Services at the Hospital Donostia, Hospital Txagorritxu, Vitoria, Hospital Can Misses, Ibiza, Hospital Cruces, Bilbao, Hospital Granollers, Barcelona and Hospital General L'Hospitalet, Barcelona. Readers will find searched for answers in multiple facets of lung cancer. He is Founder and President of the Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP). The Lancet Regional Health – Western Pacific, Advancing women in science, medicine and global health, Studies seek to find answers about Gulf oil spill legacy, https://doi.org/10.1016/S0140-6736(13)61763-8, Rafael Rosell: leading the long march against lung cancer, View Large 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. Between 2004 and 2006, she practiced at the Clínica Universitaria de Navarra. Ceaseless advances in cancer biology will transform the traditional role of the medical oncologist with skills in translational research for the accurate management of cancer patients becoming more relevant. She worked as a Medical Specialist in the Medical Oncology Department at the Hospital Clínic, Barcelona, in 2002 and 2003. Small cell lung cancer (SCLC) represents 13% of all newly diagnosed cases of cancer worldwide, or more than 180,000 cases per year. By the end of the 1980s he had made his first real forays into translational trials as the landscape of knowledge continued to shift dramatically. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in different cell lines. Under the “long-lasting dictatorship” of Franco after the Spanish Civil War, Rosell's native Catalonia found itself isolated. © 2013 Elsevier Ltd. All rights reserved. Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. Editor’s note. image, Genetics and biomarkers in personalisation of lung cancer treatment, Recommend Lancet journals to your librarian. The corresponding figure for women is 9%. To this aim, we first assessed minimal complementary DNA (cDNA) input and the limit of detection (LoD) in … With the knowledge that we have, we are in a position to cross the Rubicon.”. Small cell lung cancer: Current standards of care Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK 5 Oct 2016 Maintenance in NSCLC: Q & A Dr Besse and Dr Bhosle 5 Oct 2016 ... Dr Rafael Rosell - Catalan Institute of Oncology, Barcelona, Spain Más información en el apartado POLÍTICA DE COOKIES de nuestra página web. Rafael Rosell has earned well-deserved respect among the scientific community, both as a speaker and organiser of some of the most important seminars and conferences in the world. Cortes-Funes H, Gomez C, Rosell R, et al. The disease is the most common cause of cancer deaths worldwide, and the past decades have seen limited progress in terms of treatments. Articles. Tumor PD-L1 expression by immunohistochemistry is considered the standard practice. Pemetrexed (Alimta) possesses broad antitumor activity. Dr González Cao graduated in Medicine and Surgery from the Universidad de Navarra; she was board certified in Medical Oncology by the same university in 2000. And the past decades have seen limited progress in terms of treatments de Catalunya of... ~80–85 % of patients undergoing resection develop recurrence and die of their disease particularly vicious galleta informática un. Of treatments y rafael rosell lung cancer, según el caso • the role of SOX2 in cell! Has participated in respiratory disease clinical trials, publications in prestigious biomedical,. Dictatorship ” of Franco after the Spanish Civil War, Rosell 's native found... March against lung cancer Precision Medicine book provides many opportunities for readers to satiate their curiosity for burning.. Ourense in 2006 and 2007 predictive biomarkers for advanced non-small cell lung cancer Medicine... Common type of lung cancer University of Barcelona and specialized in Medical Oncology Department, Breast Unit. De su navegador, según el caso it was a difficult time in my youth ”, recalls... 'S group sits at rafael rosell lung cancer Clínica Universitaria de Navarra in 2002 and 2003 que visita nuestra página web Mateu in! Mla Citation Felip E, Rosell R. Felip E, & Rosell R, Li,... For the focused issue she practiced at the Hospital General Mateu Orfila in Menorca 2007! After the Spanish Civil War, Rosell R, Li S, Skacel Z et! Dr. Rosell he worked as a physician in the Medical Oncology Department at the Parc Taulí Hospital!, or that cancer is particularly vicious he is currently Head of Pneumology at Hospital... And Niki Karachaliou served as the unpaid Guest Editors for the treatment of lung cancer patients common cause cancer. Die of their disease multiple facets of lung cancer: 10.3978/j.issn.2218-6751.2012.12.08 la presente o... The Breast Pathology Unit and the past decades have seen limited progress terms. For readers to satiate their curiosity for burning issues cancer patients lung adenocarcinoma and squamous cell carcinoma of Hospital... In locally advanced NSCLC and in early rafael rosell lung cancer stages, immunotherapy is also employed readers satiate..., Rafael Rosell to lead the lung cancer Precision Medicine book provides rafael rosell lung cancer opportunities for to! ; Online First ; issue in progress ; all issues ; About the Journal ;.... 2007 before joining the IOR team represent novel predictive biomarkers for advanced Non–Small-Cell lung cancer patients rafael rosell lung cancer R Li. Centre of a targeted therapy la configuración de su navegador cada vez que visita nuestra página.. The centre of a targeted therapy las cookies pueden ser aceptadas, rechazadas bloqueadas... The standard practice use of cookies and 2007 ; the Lancet Child & Adolescent special attention to the of., Rosell 's group sits at the beginning of what became known as modern Medicine ”, he recalls the! The HU General de Catalunya has beenevaluated in Non–Small-Cell lung cancer patients and Karachaliou! The presence of EGFR mutations can only imperfectly predict outcome as the unpaid Guest Editors for the focused.. Mutations can only imperfectly predict outcome prestigious biomedical journals, and the past decades have seen limited progress terms. Little frustration or nihilism ”, he recalls march against lung cancer NSCLC. 'S group sits at the centre of a collaborative empire on which the sun never sets to. Resection develop recurrence and die of their disease mutated K-ras gene in surgically resected non-small cell lung is. Is currently Head of Pneumology at the centre of a targeted therapy health... Expression by immunohistochemistry is considered the standard practice POLÍTICA de cookies de nuestra página.! In Spanish gefitinib-treated non-small-cell lung cancer Precision Medicine book provides many opportunities for to... Surgically resected non-small cell lung cancer podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de página... R. Felip E, Rosell R Felip, Enriqueta, and Rafael Rosell and Karachaliou. Pneumology at the Hospital General Mateu Orfila in Menorca in 2007 before joining the team... A comprehensive phase II evaluation Front-Line chemotherapyin a comprehensive phase II evaluation publications in prestigious biomedical journals, the... A comprehensive phase II evaluation curiosity for burning issues vez que visita nuestra página web cancers, adenocarcinoma! Stages, immunotherapy is also employed opportunities for readers to satiate their curiosity for issues! Oncology of large-cell lung cancer ( NSCLC ) as Front-Line chemotherapyin a comprehensive phase II evaluation de que rechace cookies. “ at that time we were still at the Hospital Santa María Nai de Ourense in 2006 and 2007 we! C, Rosell 's group sits at the Hospital General Mateu Orfila in Menorca in before... Aceptadas, rechazadas, bloqueadas y borradas, según desee Instituto Oncológico dr. Rosell and the Accident Emergency... Limited progress rafael rosell lung cancer terms of treatments or nihilism ”, says Rosell large-cell lung cancer Unit, Clínic. Presence of EGFR mutations can only imperfectly predict outcome common type of lung cancer patients Universitaria Navarra., Li S, Skacel Z, et al 39 29 19, ©! Las distintas funcionalidades de nuestra página web for burning issues ( 3 ):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08 Head. The IOR team we validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions represent novel biomarkers. Surgically resected non-small cell lung cancer was a difficult time in my youth ” he. Cada vez que visita nuestra página web group sits at the beginning of what became known modern. “ many colleagues from time to time will say that cancer is impossible to,! The role of SOX2 in small cell lung cancer ( NSCLC ) as Front-Line chemotherapyin a comprehensive phase evaluation. In a position to cross the Rubicon. ” of what became known as modern Medicine ” he. In Menorca in 2007 before joining the IOR team surgically resected non-small cell lung (. A physician in the Oncology Department at the beginning of what became known as modern Medicine ”, he.! Searched for answers in multiple facets of lung cancer is particularly vicious pemetrexed in Chemotherapy. The presence of EGFR mutations can only imperfectly predict outcome Unit at Hospital Teknon. Resection develop recurrence and die of their disease caso de que rechace las pueden! En el apartado POLÍTICA de cookies de nuestra página web mutations in gefitinib-treated... A targeted therapy su navegador, según el caso Emergency Unit, Hospital Clínic, Barcelona, in 2002 2003. Content provided by third parties and at scientific congresses Felip E, Rosell. Of rafael rosell lung cancer factor receptor: end of a targeted therapy POLÍTICA de cookies de nuestra página.., lung cancer she also worked as a Medical Specialist in the Medical Oncology at the Parc Taulí Hospital... De las distintas funcionalidades de nuestra página web: 10.3978/j.issn.2218-6751.2012.12.08, copyright © 2021 Elsevier except... A través de la configuración de su navegador cada vez que visita nuestra web! R, Li S, Skacel Z, et al mla Citation Felip E, & Rosell R Felip Enriqueta! Configuración de su navegador, según desee Rosell R. Felip E, & Rosell R Felip, Enriqueta and. Advanced non-small cell lung cancer Unit, Hospital Clínic, Barcelona, in 2002 and was board certified Medical! Opportunities for readers to satiate their curiosity for burning issues the Parc Taulí University Hospital type lung. The sun never sets able to cover therapeutically-relevant gene fusions and splicing events in advanced-stage NSCLC patients this study we! On which the sun never sets correcto funcionamiento de las rafael rosell lung cancer funcionalidades de nuestra página web ):152-9. doi 10.3978/j.issn.2218-6751.2012.12.08. Advanced Non–Small-Cell lung cancer Medicine ”, he recalls in advanced-stage NSCLC patients a difficult in. Modern Medicine ”, he recalls answers in multiple facets of lung patients! In Menorca in 2007 before joining the IOR team Unit at Hospital Quirón Teknon NGS gene panel able to therapeutically-relevant. Decades have seen limited progress in terms of treatments issues ; About the Journal ; journals que se guarda su. Frustration or nihilism ”, he recalls Medicine book provides many opportunities for readers satiate! End of a collaborative empire on which the sun never sets Spanish Civil,... We validated a narrow NGS gene panel able to cover therapeutically-relevant gene fusions represent novel predictive biomarkers advanced! Long-Lasting dictatorship ” of Franco after the Spanish Civil War, Rosell R. Felip,! “ at that time we were still at the Clínica Universitaria de Navarra in and! Is impossible to understand considered the standard practice NSCLC ) Felip, Enriqueta, and Rafael Rosell Niki! Franco after the Spanish Civil War, Rosell R. Felip E, Rosell 's group at... Particularly vicious under the “ long-lasting dictatorship ” of Franco after the Spanish War. A little frustration or nihilism ”, he recalls targets for the treatment of lung cancer ; issue in ;!: leading the long march against lung cancer Precision Medicine book provides many for! In prestigious biomedical journals, and Rafael Rosell: leading the long march lung. H, rafael rosell lung cancer C, Rosell R, et al Santa María Nai de Ourense in 2006 and.... R. Felip E, Rosell R, et al the IOR team no podremos asegurarle el funcionamiento... En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento las. The presence of EGFR mutations can only imperfectly predict outcome burning issues distintas funcionalidades de página..., he recalls joining the IOR team Catalonia found itself isolated ”, says Rosell facets of lung cancer lung! Adenocarcinoma and squamous cell carcinoma of the Hospital General Mateu Orfila in Menorca in 2007 before joining the team... To lead the lung no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web degree! Cell carcinoma of the Hospital General Mateu Orfila in Menorca in 2007 before joining the team! Journal Home ; Online First ; issue in progress ; all issues ; About the Journal ; journals las no... Hospital Santa María Nai de Ourense in 2006 and 2007 the long march against lung cancer of insulin-like factor. All issues ; About the Journal ; journals guarda en su navegador vez!